• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

17-OHPC Treatment and Prevention of Preterm Birth: Does Timing Matter?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • The current SMFM guideline recommends
    • 250 mg 17-OHPC IM weekly starting at 16-20 weeks of gestation until 36 weeks of gestation or delivery
  • Ning et al. (AJOG, 2017) examined the relationship between the gestational age at 17-OHPC initiation in women with prior preterm birth

 METHODS:

  • Retrospective cohort study
  • Women included were those who had ≥ 1 previous spontaneous preterm birth between 16 and 28 weeks with one of the following:
    • Spontaneous onset of contractions
    • Preterm PROM
    • Painless cervical dilation
  • Women were grouped based on quartiles of gestational age of initiation
    • Early-Start: Quartile 1 (140/7 to 161/7) + Quartile 2 (162/7 to 170/7)
    • Late-Start: Quartile 3 (171/7 to 186/7) + Quartile 4 (190/7 to 275/7)
  • Primary Outcomes:
    • Recurrent preterm birth <37 weeks’ gestation
  • Secondary outcomes:
    • Recurrent preterm birth <34 and <28 weeks’ gestation
    • Composite major neonatal morbidity (diagnosis of grade III or IV intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, necrotizing enterocolitis stage II or III, or death)

 RESULTS:

  • 132 women met inclusion criteria
  • 39% delivered < 37 weeks
  • 17-OHPC was initiated at a mean 17 weeks 5 days ± 2.5 weeks
  • Women with Early-Start trended toward lower rates of recurrent preterm birth <37 weeks compared to Late-Start (41.3% compared to 57.7%, P= 0.65) but not statistically significant
  • Women with Early-Start had a later mean delivery gestational age (37.0 ± 3.1 weeks vs 35.0 ± 5.1 weeks for women with late-start 17-OHPC [P = .008])
  • In regression models, odds of preterm birth were increased based on
    • Later Initiation Quartile
    • Short cervical length (<25 mm) in the midtrimester
    • Prepregnancy BMI ≥30 kg/m2
  • Delivery gestational age was inversely proportional to gestational age at initiation
    • quartile 1, 37 weeks 4 days vs quartile 2, 36 weeks 5 days vs quartile 3, 36 weeks 1 day vs quartile 4, 34 weeks 0 days; P = .007
  • Early-Start had lower rates of major neonatal morbidity compared to Late-Start  (1.5% vs 14.3%, P = .005)

 CONCLUSION:

  • Rates of recurrent preterm birth among women with a prior spontaneous preterm birth 16-28 weeks are high
  • Women beginning 17-OHPC earlier deliver later and have improved neonatal outcomes
  • Authors recommend initiation at 16 weeks and to study whether even earlier initiation may be appropriate for higher risk patients

 Learn More – Primary Sources:

Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Preventing Preterm Birth in Twins – What works?
SMFM Statement: Choice of Progestogen for Preterm Birth Prevention

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site